UPDATE: Roth Capital On KalVista Buy Reiteration: Firm Remains Bullish On Co.'s On-Demand HAE Treatment Following Phase 2 Data With Significant Results Shown In Comparison To Placebo As Symptom Relief Occurred At 1.6 Hours Vs. 9 Hours Respectively